Alkem Laboratories Limited has accepted the resignation of Dr. Jitendra Singh Huda from the position of Senior Vice President, effective July 23, 2026. The pharmaceutical company disclosed that Dr. Huda tendered his resignation to pursue professional growth opportunities. Consequently, he will cease to hold his senior management position within the organization starting from the stated date, marking a leadership transition in its senior management team.

The resignation process was initiated via email on July 14, 2026, and formally accepted by Dr. Rajorshi Ganguli, President and Global HR Head, on July 15, 2026. In his resignation communication, Dr. Huda confirmed his availability until July 23, 2026, to complete pending responsibilities and ensure a smooth handover of duties. The company acknowledged the valuable contributions made by Dr. Huda during his tenure as Senior Management Personnel.

Regulatory Disclosure

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Divya Mewani, Vice President – Legal & Deputy Company Secretary. The company also referenced SEBI Master Circular bearing No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, in its submission.

The specific details regarding the change in senior management were provided in Annexure I to the regulatory filing. A copy of the resignation letter tendered by Dr. Huda was enclosed as Annexure II. The information is also available on the company’s website.

Key Details of Resignation

Alkem Laboratories has completed the acquisition of a 51-55% stake in Swiss medical device manufacturer Occlutech Holding AG through its wholly owned subsidiary, Alkem Medtech Private Limited. The transaction, executed pursuant to a Share Purchase Agreement, results in Occlutech becoming a step-down subsidiary of Alkem Laboratories. The disclosure was submitted to the stock exchanges under Regulation 30 of the SEBI LODR Regulations.

To facilitate this acquisition, Alkem Laboratories had previously infused capital into Alkem Medtech. This involved the acquisition of 79,36,50,794 equity shares for a total cash consideration of ₹1,100 crore via a rights issue at an allotment price of ₹13.86 per share. The shares were allotted on July 15, 2026.

Financial Details of the Transaction

The following table outlines the key financial metrics related to the capital infusion for the acquisition:

Background of Alkem Medtech

Alkem Medtech is a wholly owned subsidiary of Alkem Laboratories in India. Incorporated on March 27, 2024, the entity operates in the medical device sector with a focus on cardiovascular and orthopedic fields. For the financial year ended March 31, 2026, Alkem Medtech reported a turnover of ₹15.13 crore, compared to nil in the previous financial year. The subsidiary is strategically positioned to support the company's expansion into the medical device segment.